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Abstract. HURP gene encodes the hepatoma upregu‑
lated protein (HURP), a microtubule associated protein 
regulating mitotic spindle dynamics, which promotes 
chromosomal congression and alignment during mitosis, 
with a potential role in tumorigenesis. In the present study, 
HURP mRNA expression was investigated by reverse 
transcription‑quantitative PCR in oropharyngeal squamous 
cell carcinoma (OPSCC). Primary OPSCC tumors from 
107 patients and 48 adjacent normal tissues, as well as 
12 respiratory tract cancer cell lines (9 head and neck squa‑
mous cell carcinoma, 2 lung cancer and 1 normal bronchial) 
were utilised in the present study. mRNA expression levels 
of HURP were higher in malignant OPSCC tissues compared 
with in normal mucosa (P<1x10‑5) and significantly associ‑
ated with sex and smoking status (P<0.0001). Vinorelbine 
in vitro toxicity at half‑maximal inhibitory concentration 
(IC50) was measured in the 11 cancer cell lines using an 
MTT assay. Sensitivity to vinorelbine was significantly 
correlated with HURP expression (r=0.636; P=0.035). The 
data indicated that HURP overexpression is frequent in 
OPSCC tissues and associated with smoking. The correlation 
between HURP mRNA expression and vinorelbine in vitro 
response suggests that HURP is a potential modulator of 
vinorelbine response; therefore, it should be explored for its 
possible predictive value for the efficiency of vinorelbine 
treatment in this type of cancer.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is a collec‑
tive term to describe malignant tumors of the nasal cavity, 
nasopharynx, larynx and oral cavity. HNSCC represents the 
sixth most common malignancy worldwide (1). The main risk 
factors for developing HNSCC cancer are: a) the synergistic 
effect of tobacco smoking and alcohol consumption (2,3), 
b) viral infections such as human papillomavirus (HPV) (4) 
Epstein–Barr virus (EBV) (5), and c) genetic predisposition (6). 
Accumulated molecular evidence in recent years has proved that 
HPV is a key risk factor for increasing incidence of oropharyn‑
geal squamous cell carcinoma (OPSCC) (7‑9). Vinorelbine is an 
antimitotic agent, which belongs to the vinca alkaloids family 
and is effectively used to treat a variety of cancer cases. Some 
in vitro studies on HNSCC cells have reported an additive effect 
of vinorelbine to radiation exposure (10,11). In clinical trials, 
vinorelbine administration has also brought clinical benefits for 
treating advanced, recurrent/metastatic cases of head and neck 
squamous cell carcinoma (12‑18). This indicates a clinical need 
to identify the cases that would benefit from vinorelbine. It is 
essential, therefore, to explore potential biomarkers that have 
predictive value for vinorelbine based therapy of HNSCC cases 
alongside the disease prognosis.
Vinorelbine affects MT dynamics and prevents formation of 
the mitotic spindle, resulting in metaphase arrest deregulation 
of HURP expression, in relation (19). Therefore, the overex‑
pression of genes involved in spindle assembly and microtubule 
dynamics could mediate vinorelbine chemo‑resistance. HURP 
protein is encoded by HURP or DLGAP5 (Disks large‑associ‑
ated protein 5) gene, located on chromosome 14q22.3. HURP 
is a MAP protein associated with kinetochore MTs, that plays 
a critical role in spindle assembly, chromosome congres‑
sion, alignment and segregation (20‑23) and has a previously 
reported to be involved in tumorigenesis (24,25). Hence, it can 
be hypothesised that HURP expression may predict response 
to vinorelbine in cancer cells.
Elevated levels of HURP mRNA transcripts have been 
reported in lung cancer (26) and potentially associated with 
prognostication (27). The predictive value of HURP expres‑
sion for radiotherapy has also been reported in prostate cancer 
cells (28). Increased HURP mRNA expression has also been 
Overexpression of HURP mRNA in head and neck carcinoma 
and association with in vitro response to vinorelbine
AHMED S. K. AL‑KHAFAJI1,2,  PASCHALIA PANTAZI2,  AMELIA ACHA‑SAGREDO2,  
ANDREW SCHACHE2,  JANET M. RISK2,  RICHARD J. SHAW2  and  TRIANTAFILLOS LILOGLOU2
1Department of Biology, College of Science, University of Baghdad, Baghdad 10070, Iraq;   
2Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, 
University of Liverpool, Liverpool L7 8TX, UK
Received July 12, 2019;  Accepted November 6, 2019
DOI:  10.3892/ol.2020.11339
Correspondence to: Dr Triantafillos Liloglou, Department of 
Molecular and Clinical Cancer Medicine, Institute of Translational 
Medicine, University of Liverpool, 6 West Derby Street, 
Liverpool L7 8TX, UK
E‑mail: tliloglo@liverpool.ac.uk
Key words: hepatoma upregulated protein, head and neck 
squamous cell carcinoma, oropharyngeal squamous cell 
carcinoma, vinorelbine, mRNA expression, smoking, human 
papillomavirus
AL‑KHAFAJI et al:  HURP EXPRESSION IN HEAD AND NECK CANCER2
observed in oral squamous cell carcinoma (OSCC) (29) and 
anaplastic thyroid carcinoma (ATC) (30).
In this study, we evaluated HURP mRNA expression in a 
large group of oropharyngeal tumors and investigated potential 
associations with clinicopathological characteristics. In addi‑
tion, we explored the involvement of HURP mRNA expression 
in the in vitro response to vinorelbine, which is a commonly 
used agent for the management of late stage HNSCCs.
Materials and methods
Patients and specimens. Clinicopathological data (gender, age, 
and lymph node involvement) were anonymously provided 
based on the ethical approval already granted (South Sefton 
Research Ethics Committee; EC.47.01‑6 & North West 5 
Research Ethics Committee; 09.H1010.5). Primary OPSCC 
tissues were available from 107 patients. Normal adjacent 
mucosa was available from 48 of these patients. Snap frozen 
biopsies were cryo‑sectioned using OCT embedding matrix 
(CellPath Ltd.) to embed frozen blocks for cryosectioning 
using Cryostat (Thermo Fisher Scientific, Inc.). A 5‑mm 
section fixed in 10% buffered formalin (cat. no. UN 2209, 
AnalaR) and stained with hematoxylin (cat. no. 6765003, 
Thermo Fisher Scientific, Inc.) and eosin (cat. no. 6766007, 
Thermo Fisher Scientific, Inc.) for histopathological examina‑
tion was followed by two 10 mm sections that were utilised for 
RNA extraction.
Cell lines and growth conditions. Cancer cell lines 
utilised in this study were taken from the repositories of 
the Head and Neck group biobank and the Liverpool Lung 
Project biobank. All of them are established cell lines 
representing squamous cell carcinoma of head and neck 
(UPCI‑SCC090 ) OPSCC, PE/CA‑PJ41 (oral squamous epithe‑
lium), PE/CA‑PJ15 (oral, tongue), UMSCC19 (oropharyngeal, 
base of tongue), UMSCC12 (laryngeal), UMSCC104 (oral, 
floor of mouth), UMSCC4 (oropharyngeal base of tongue), 
HN5 (oral), UMSCC81B (oropharyngeal, tonsil/glottic 
laryngeal), adenocarcinoma of lung (A549 and CALU6) and 
a normal non‑tumorigenic immortalized bronchial cell line 
(HBEC‑3KT) (31). Cell lines examined in this study were 
authenticated (GenePrint 10 System; Promega Corporation) 
and mycoplasma tested (Myco™ plus Mycoplasma PCR 
Detection kit; iNtRON  Biotechnology).
All cancer cell lines were maintained in Dulbecco's 
modified Eagle's medium (DMEM)/Ham's Nutrient Mixture 
F‑12 (1:1) containing 5% fetal bovine serum (Sigma‑Aldrich; 
Merck KGaA). HBEC‑3HT cell line was cultured in 
Keratinocyte‑SFM medium supplemented with 50 mg/ml 
bovine pituitary extract (BPE) and 5 ng/ml human recom‑
binant epidermal growth factor (rEGF) (Life Technologies; 
Thermo Fisher Scientific, Inc.). All cell lines were maintained 
at 37̊C, 5% CO2.
RNA extraction and reverse transcription‑quantitative 
PCR (RT‑qPCR). Total RNA was extracted utilising the 
Direct‑zol™ RNA MiniPrep kit (Zymo Research Corp.), 
quantified using a NanoDrop 2000 Spectrophotometer 
(Thermo Fisher Scientific, Inc.) and reverse transcribed 
utilising the High Capacity cDNA Reverse Transcription kit 
(Life Technologies; Thermo Fisher Scientific, Inc.), according 
to the manufacturers' instructions. For RT‑qPCR, primers and 
probe for ACTB were designed using the OLIGO 7 software 
(Molecular Biology Insights) (forward: 5'‑GGC ACC CAG 
CAC AAT GAA G‑3', reverse: 5'‑CAT ACT CCT GCT TGC TGA 
TCC A‑3', probe: 5' VIC‑CTC CTC CTG AGC GCA AGT ACT 
CCG TG‑NFQ 3'), while the predesigned assay for HURP 
mRNA expression (Hs00207323‑m1) was purchased from 
Thermo Fisher Scientific, Inc. RT‑qPCR assays were performed 
in 2 replicates for clinical specimens and 4 replicates for cell 
lines. mRNA expression levels were calculated as relative 
quantification (RQ) values, based on the equation RQ = 2‑ΔΔCq, 
where Cq represents quantification cycle values that deter‑
mined by StepOne software (version 1.2; Thermo Fisher 
Scientific, Inc.) and normalised to the corresponding Cq value 
for the endogenous control ACTB, generating ΔCq values 
(ΔCq = Cq target‑Cq ACTB). Sample ΔCq values were further 
normalised against HBEC‑3KT control using the formula: 
ΔΔCq = (ΔCq sample‑ΔCq HBEC‑3KT) (32). HPV status of 
the tumors in the study was previously detected (33,34).
Vinorelbrine exposure. Cell line growth in the presence 
of varying concentrations of vinorelbine (0‑500 nM) was 
assessed by MTT assay. Exposure lasted for 72 h and measure‑
ments were taken from six biological repeats.
HURP mRNA expression differences across categorical 
clinicopathological parameters were assessed using the 
Mann‑Whitney test. Spearman's correlation was used to 
test the relationship between HURP mRNA expression and 
response to vinorelbine.
Statistical analysis. All statistical analyses, except the 
IC50 calculation, were performed using IBM® SPSS® statis‑
tical software (version 24.0; IBM SPSS). The vinorelbine 
IC50 values were calculated using non‑linear regression in 
Prism 5 (GraphPad Software, Inc.).
Results
Gene expression analysis. RT‑qPCR analysis in primary 
human HNSCC tissues showed that HURP transcript levels 
were significantly higher in tumor tissues compared with 
those in adjacent normal mucosa (Mann‑Whitney test, P<10‑5, 
Fig. 1).
HURP transcript levels significantly correlated with 
patients' gender (Mann‑Whitney test, P=0.019) and smoking 
status (Mann‑Whitney test, P=0.041). It has to be noted though 
that gender was associated with smoking status (χ2 test, 
P<10‑4). No association was observed between HURP mRNA 
expression and other parameters such as age, lymph node 
involvement, alcohol consumption or HPV status (Table I).
Correlation of HURP mRNA levels with vinorelbine response. 
All HNSCC and lung cancer cell lines tested here showed 
significantly higher HURP mRNA expression compared to 
that of immortalized normal HBEC cells that was used as a 
calibrator (Fig. 2). Notably, the vinorelbine response presented 
as IC50 values (Table II) in the tested cancer cell lines was asso‑
ciated with the level of HURP mRNA expression (Spearman's 
rank test, r=0.636, P=0.035).
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Discussion
HURP overexpression has been previously reported in 
a number of human respiratory malignancies, including 
non‑small cell lung cancer (NSCLC) (26,27,35) and 
OSCC (29). However, the latter study validated publically 
available microarray data on an independent set of only 
11 patients; therefore, the extent of HURP deregulation in 
Table I. Clinicopathological parameters of the patient cohort in the present study.
 95% CI
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
 Patients,  Mean Lower Upper
Parameter  n (%) (n=107) expression boundary boundary P‑valuea
Sex     0.02
  Male 82 (76.7) 99.49 23.55 175.43  
  Female 25 (23.3) 18.59 3.96 33.21  
Age, years     0.834
  <55  43 (40.2) 158.7 12.41 305.00 
  ≥55  64 (59.8) 29.31 9.05 49.57 
HPV status     0.981
  Positive 40 (37.4) 88.25 20.50 197.00 
  Negative 67 (62.6) 67.91 14.00 121.80 
Lymph node involvement     0.14
  Yes 71 (66.4) 85.18 11.54 158.82 
  No 36 (33.6) 55.48 6.18 117.14 
Tobacco use     0.04
  Yes 80 (74.8) 90.03 16.43 163.63 
  No 27 (25.2) 42.98 17.06 103.03 
Alcohol consumption     0.161
  Yes 90 (84.1) 86.83 23.58 150.09 
  No 17 (15.9) 11.65 7.38 15.93 
aP‑values derived from Mann‑Whitney test.
Figure 1. Boxplots demonstrating HURP mRNA expression levels (RQ values) 
in primary OPSCC tumors compared with in normal adjacent tissues. The 
level of HURP transcripts was significantly upregulated in OPSCC tissue 
compared with in normal tissues. P‑values were derived from Mann‑Whitney 
tests. RQ values were calculated using RNA extracted from HBEC‑3KT cells 
as a calibrator. *Extreme values (>3x interquartile range); ̊ Outlier values (>1.5x 
interquartile range). HURP, hepatoma upregulated protein; OPSCC, oropha‑
ryngeal squamous cell carcinoma; RQ, relative quantification.
Figure 2. mRNA expression levels of HURP in Respiratory Tract Center 
cell lines demonstrated that head and neck squamous cell carcinoma 
cell lines expressed higher levels of HURP transcripts, most notably 
UPCI‑UMSCC090 and PJ41 cells, compared with the normal HBEC cells. 
The bars depict the mean expression values from four replicates, whereas 
the error bars represent the 95% CI. HURP, hepatoma upregulated protein; 
RQ, relative quantification.
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HNSCCs is still unclear. In addition, as it is well established 
that HPV positive oropharyngeal tumors compose a distinct 
class from a therapeutic perspective (36), it was important to 
explore the deregulation of HURP expression, in relation to 
the tumors' HPV status. Our study included 107 oropharyn‑
geal tumors, providing a more robust figure for the reported 
overexpression. This frequent overexpression of HURP 
indicates a potential role in OPSCC pathogenesis. This is not 
surprising since HURP regulates mitotic activity of spindle 
assembly (20‑23), therefore alterations in its expression 
lead to defects in cell division and aneuploidy, contributing 
eventually to tumorigenesis. This is further supported by the 
observation that knockdown of HURP leads to inhibition 
of proliferation of human pharyngeal squamous carcinoma 
cells (37). The tumorigenic activity of HURP has also been 
reported in breast cancer (24), hepatocellular carcinoma 
(HCC) (25) and ATC (30,38) indicating its important role in 
human cancer development.
Higher HURP mRNA levels were significantly associated 
with smoking in our study. This result is consistent with the fact 
that tobacco smoking is a well‑known risk factor of HNSCC 
cancer alongside alcohol consumption (2,3). Currently the 
mechanism connecting smoking with HURP deregulation 
is not known. It still needs to be elucidated whether tobacco 
use has a causative role in this deregulation or whether it is 
a secondary effect of tobacco‑induced carcinogenesis. The 
association with gender appears to be coincidental due to the 
significant correlation between smoking and gender in our 
dataset, which fits the recognised pattern (males smoke more) 
in the UK (https://www.cancerresearchuk.org/health‑profes‑
sional/cancer‑statistics/risk/tobacco#heading‑One).
The lack of correlation between HURP mRNA expres‑
sion and stage and nodal status of the tumors suggests this 
is an early event in OPSCC tumorigenesis. Furthermore, no 
correlation with HPV status was observed. However, one has 
to consider the fact that most of these HPV positive patients 
were also smokers, which may be a confounding factor in this 
analysis; therefore, a much larger cohort would be required to 
enable proper stratification between those parameters.
Vinorelbine has been studied for its clinical efficiency in 
treating HNSCC (10,11,39,40); however it has been used in 
late/recurrent stages only (12‑18,41). To date, no biomarkers 
have been suggested as possible companion indicators for 
vinorelbine treatment in head and neck cancer. However some 
potential biomarkers have been suggested for predicting VRL 
efficiency in lung cancer (42,43). Our study is the first to suggest 
a possible role in predicting response to vinorelbine in vitro. A 
possible explanation behind the correlation we report is possibly 
related with the ability of HURP to bind directly to MTs and 
regulate their dynamics (21,22) while vinorelbine blocks mitosis 
by suppressing MT dynamics (19). Taken together, both lines of 
evidence may suggest HURP overexpression may be a poten‑
tial predictor for resistance to vinorelbine‑involving regimens 
in HNSCC patients. The next step is to expand this study to 
samples from relevant clinical trials involving vinorelbine, 
in order to establish the efficiency of HURP expression as a 
predictor for vinorelbine administration.
In conclusion, our study demonstrates for the first time the 
significant overexpression of HURP mRNA in OPSCC and 
its association with smoking. It also provides initial in vitro 
evidence for the potential role of HURP in resistance against 
antineoplastic agent vinorelbine. Future studies are required 
to uncover its potency to serve as a therapeutic stratification 
marker in regimens including this antimitotic agent, incorpo‑
rating the fact that VRL is always used in combination with 
another chemotherapeutic agent.
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